Brendan P. Eckelman's Insider Trades & SAST Disclosures
Brendan P. Eckelman's most recent trade in Inhibrx Biosciences Inc. was a trade of 433,888 Common Stock done . Disclosure was reported to the exchange on May 29, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Brendan P. Eckelman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. | Brendan P. Eckelman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 433,888 | 433,888 | - | - | Common Stock | |
| Inhibrx Biosciences Inc. | Brendan P. Eckelman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Inhibrx Biosciences Inc. | Brendan P. Eckelman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 40,000 | 40,000 | - | - | Common Stock | |
| Inhibrx Biosciences Inc. | Brendan P. Eckelman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 40,000 | 40,000 | - | - | Common Stock | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 2,510 | 6,667 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 2,500 | 26,667 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 1,898 | 9,177 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 19,898 | 11,075 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 6,877 | 30,973 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 6,681 | 33,319 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 4,152 | 29,167 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 2,150 | 37,850 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.20 per share. | 01 Mar 2023 | 39,600 | 2,035,953 | - | 24.2 | 958,348 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.71 per share. | 01 Mar 2023 | 400 | 2,035,553 | - | 24.7 | 9,883 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.08 per share. | 01 Feb 2023 | 14,608 | 2,087,496 | - | 25.1 | 366,366 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.29 per share. | 01 Feb 2023 | 13,449 | 2,102,104 | - | 24.3 | 326,710 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.40 per share. | 01 Feb 2023 | 10,120 | 2,076,683 | - | 25.4 | 257,094 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.89 per share. | 01 Feb 2023 | 1,130 | 2,075,553 | - | 25.9 | 29,261 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.66 per share. | 01 Feb 2023 | 693 | 2,086,803 | - | 25.7 | 17,780 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.41 per share. | 03 Jan 2023 | 22,213 | 2,133,340 | - | 23.4 | 520,051 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.36 per share. | 03 Jan 2023 | 8,598 | 2,124,742 | - | 24.4 | 209,426 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.11 per share. | 03 Jan 2023 | 4,102 | 2,118,556 | - | 23.1 | 94,786 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.99 per share. | 03 Jan 2023 | 3,003 | 2,115,553 | - | 24.0 | 72,043 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 03 Jan 2023 | 2,084 | 2,122,658 | - | 25.1 | 52,293 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.83 per share. | 06 Dec 2022 | 20,927 | 2,174,626 | - | 26.8 | 561,572 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.57 per share. | 06 Dec 2022 | 17,681 | 2,156,945 | - | 27.6 | 487,493 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.46 per share. | 06 Dec 2022 | 1,392 | 2,155,553 | - | 28.5 | 39,617 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.33 per share. | 01 Nov 2022 | 27,651 | 2,207,902 | - | 33.3 | 921,746 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.90 per share. | 01 Nov 2022 | 12,349 | 2,195,553 | - | 33.9 | 418,641 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.78 per share. | 04 Oct 2022 | 11,136 | 2,256,762 | - | 26.8 | 298,182 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.68 per share. | 04 Oct 2022 | 10,893 | 2,235,653 | - | 29.7 | 323,302 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.06 per share. | 04 Oct 2022 | 6,207 | 2,267,898 | - | 26.1 | 161,763 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.97 per share. | 04 Oct 2022 | 5,954 | 2,246,546 | - | 29.0 | 172,495 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 04 Oct 2022 | 4,262 | 2,252,500 | - | 27.8 | 118,299 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.67 per share. | 04 Oct 2022 | 1,448 | 2,274,105 | - | 24.7 | 35,720 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.52 per share. | 04 Oct 2022 | 100 | 2,235,553 | - | 30.5 | 3,052 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Sep 2022 | 160,000 | 2,275,553 | - | 0 | Common Stock | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Sep 2022 | 80,000 | 160,000 | - | 0 | Common Stock | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Sep 2022 | 80,000 | 160,000 | - | 0 | Common Stock | |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.86 per share. | 06 Sep 2022 | 37,507 | 2,438,046 | - | 14.9 | 557,241 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.66 per share. | 06 Sep 2022 | 2,493 | 2,435,553 | - | 15.7 | 39,032 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.70 per share. | 02 Aug 2022 | 24,500 | 2,491,053 | - | 17.7 | 433,626 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.47 per share. | 02 Aug 2022 | 15,500 | 2,475,553 | - | 18.5 | 286,209 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.17 per share. | 07 Jul 2022 | 40,000 | 2,515,553 | - | 17.2 | 686,800 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 05 Apr 2022 | 400 | 2,555,553 | - | 25.0 | 10,016 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.02 per share. | 24 Mar 2021 | 17,000 | 2,555,953 | - | 19.0 | 323,340 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 16 Feb 2021 | 17,000 | 2,572,953 | - | 25.9 | 440,300 | Common Stock |
| Inhibrx Inc | Brendan P. Eckelman | Director, Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Jan 2021 | 160,000 | 2,589,953 | - | 0 | Common Stock | |
| Inhibrx Inc | Brendan P. Eckelman | Director, Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Jan 2021 | 80,000 | 80,000 | - | 0 | Common Stock | |
| Inhibrx Inc | Brendan P. Eckelman | Director, Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Jan 2021 | 80,000 | 80,000 | - | 0 | Common Stock | |
| Inhibrx Inc | Brendan P. Eckelman | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges